Psychoactive Substance Use DisorderPSYCHO'ACTNCT05115981
Psychoactive Drug Uses Among Medical and Pharmacy Students
An observational study of Psychoactive Substance Use Disorder, run by University Hospital, Grenoble at 1 site in France.
Trial summary
Drug addiction to psychoactive substances, widely consumed in France, represents a major public health issue. The three main motivations identified for the consumption of psychostimulants would be self-medication, the party aspect and the improvement of school performance. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Psychoactive Substance Use Disorder
- How many people
- 1,930 participants
- Where
- 1 siteFrance
- Study dates
- 24 Jan 2022to 21 Mar 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: medical and pharmacy students, from the 2nd to the 6th year, in France
Who may be able to join
- Being of legal age
- Studying medicine or pharmacy in France from the 2nd to the 6th year
- Have read the newsletter and validated its no objection
- Have answered all the questions
- Validate the return of the questionnaire
Who cannot join
- partial filling of the online questionnaire
Trial locations and contacts
1 site in 1 country.
About this study
Drug addiction to psychoactive substances, widely consumed in France, represents a major public health issue. The three main motivations identified for the consumption of psychostimulants would be self-medication, the party aspect and the improvement of school performance. Students of medicine and pharmacy are a population exposed to academic and professional stress, vulnerable to health problems and psycho-social disorders (anxiety, depression), with direct access to many drugs at their workplace. Almost a third of these students declared to consume these products to improve their cognitive performance, while a recent study showed that they take them instead to manage their stress and sleep. However, no study has characterized all the different uses of psychoactive drugs (PAD) in this population, nor the motivations for consumption, while an analysis of motives would help to develop better screening and prevention strategies. The main objective of the research is to characterize the motivations for PAD consumption among students of medicine and pharmacy in France. The most represented motives will be analyzed on the questionnaire of motivations for consumption (threshold frequency ≥20%). The secondary objectives are to identify the risk factors linked to the individual, to the environment and to drugs in students with PAD use disorders regardless of their motivation and in those using to improve their performance.
- Conditions
- Psychoactive Substance Use Disorder
What is being measured
The primary outcome is the main question the study is designed to answer.
The main objective of the research is to characterize the motivations for psychoactive drugs consumption among medical and pharmacy students in France.
frequency of the most represented items concerning the main palatability drug on the Consumption Motivation Screening Questionnaire (frequency threshold considered ≥ 20%).
(the minimum value of the questionnaire: 0 motivation of consumption; the maximum value: 110 motivations of consumption, higher scores mean a more severe addiction)
Measured: two months
Secondary outcomes (8)
In students with a psychoactive drug use disorder whatever their motivations, identify the risk factors related to the individual (anxiety)
assessment the intensity of anxiety on the Hospital Anxiety and Depression scale (the minimum value of the scale : 0 for Anxiety, 0 for Depression; the maximum value: 21 for Anxiety, 21 for depression; higher scores mean a worse outcome)
Measured: two months
In students with a psychoactive drug use disorder whatever their motivations, identify the risk factors related to the individual (depression)
assessment the intensity of depression on the Hospital Anxiety and Depression scale (the minimum value of the scale : 0 for Anxiety, 0 for Depression; the maximum value: 21 for Anxiety, 21 for depression; higher scores mean a worse outcome)
Measured: two months
In students with a psychoactive drug use disorder whatever their motivations, identify the risk factors related to the environment
family psychiatric history Psycho'act questionnaire
Measured: two months
In students with a psychoactive drug use disorder whatever their motivations, identify the risk factors related to drugs.
assessment of the intensity of the psychoactive drug use disorder with the Addictive Intensity Evaluation Questionnaire (the minimum value of the questionnaire : 14; the maximum value: 98; higher scores mean a worse outcome)
Measured: two months
In students with psychoactive drug use disorder for doping purposes, identify risk factors related to the individual (anxiety)
assessment the intensity of anxiety on the Hospital Anxiety and Depression scale (the minimum value of the scale : 0 for Anxiety, 0 for Depression; the maximum value: 21 for Anxiety, 21 for depression; higher scores mean a worse outcome)
Measured: two months
In students with psychoactive drug use disorder for doping purposes, identify risk factors related to the individual (depression)
assessment the intensity of depression on the Hospital Anxiety and Depression scale (the minimum value of the scale : 0 for Anxiety, 0 for Depression; the maximum value: 21 for Anxiety, 21 for depression; higher scores mean a worse outcome)
Measured: two months
In students with psychoactive drug use disorder for doping purposes, identify risk factors related to the environment
family psychiatric history Psycho'act questionnaire
Measured: two months
In students with psychoactive drug use disorder for doping purposes, identify risk factors related to drugs.
assessment of the intensity of the psychoactive drug use disorder with the Addictive Intensity Evaluation Questionnaire (the minimum value of the questionnaire : 14; the maximum value: 98; higher scores mean a worse outcome)
Measured: two months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Nov 2021
- Study start24 Jan 2022
- Primary completion21 Mar 2022
- Study completion21 Mar 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Psychoactive Substance Use DisorderStudies of the same condition, open and under way.
- More trials run by University Hospital, GrenobleThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 1,930 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Grenoble
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05115981
- Sponsor's protocol ID
- 38RC20.161
- Other IDs
- 2020-A01352-37
- Acronym
- PSYCHO'ACT
- Status last verified
- May 2022
- First submitted
- 27 Sep 2021
- Last updated
- 9 May 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 May 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Psychoactive Drug Uses Among Medical and Pharmacy Students
- ClinicalTrials.gov ID
- NCT05115981
- Acronym / sponsor ID
- PSYCHO'ACT / 38RC20.161
- Conditions
- Psychoactive Substance Use Disorder
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,930 participants (actual)
- Lead sponsor
- University Hospital, GrenobleUniversity, hospital or other
- Study start
- 24 Jan 2022 (actual)
- Primary completion
- 21 Mar 2022 (actual)
- Study completion
- 21 Mar 2022 (actual)
- First posted
- 10 Nov 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Drug addiction to psychoactive substances, widely consumed in France, represents a major public health issue. The three main motivations identified for the consumption of psychostimulants would be self-medication, the party aspect and the improvement of school performance. Students of medicine and pharmacy are a population exposed to academic and professional stress, vulnerable to health problems and psycho-social disorders (anxiety, depression), with direct access to many drugs at their workplace. Almost a third of these students declared to consume these products to improve their cognitive performance, while a recent study showed that they take them instead to manage their stress and sleep. However, no study has characterized all the different uses of psychoactive drugs (PAD) in this population, nor the motivations for consumption, while an analysis of motives would help to develop better screening and prevention strategies. The main objective of the research is to characterize the motivations for PAD consumption among students of medicine and pharmacy in France. The most represented motives will be analyzed on the questionnaire of motivations for consumption (threshold frequency ≥20%). The secondary objectives are to identify the risk factors linked to the individual, to the environment and to drugs in students with PAD use disorders regardless of their motivation and in those using to improve their performance.
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- medical and pharmacy students, from the 2nd to the 6th year, in France
Key inclusion criteria (5 listed)
- Being of legal age
- Studying medicine or pharmacy in France from the 2nd to the 6th year
- Have read the newsletter and validated its no objection
- Have answered all the questions
- Validate the return of the questionnaire
Key exclusion criteria (1 listed)
- partial filling of the online questionnaire
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The main objective of the research is to characterize the motivations for psychoactive drugs consumption among medical and pharmacy students in France.
Time frame: two months
frequency of the most represented items concerning the main palatability drug on the Consumption Motivation Screening Questionnaire (frequency threshold considered ≥ 20%). (the minimum value of the questionnaire: 0 motivation of consumption; the maximum value: 110 motivations of consumption, higher scores mean a more severe addiction)
8 secondary outcomes
In students with a psychoactive drug use disorder whatever their motivations, identify the risk factors related to the individual (anxiety)
Time frame: two months
In students with a psychoactive drug use disorder whatever their motivations, identify the risk factors related to the individual (depression)
Time frame: two months
In students with a psychoactive drug use disorder whatever their motivations, identify the risk factors related to the environment
Time frame: two months
In students with a psychoactive drug use disorder whatever their motivations, identify the risk factors related to drugs.
Time frame: two months
In students with psychoactive drug use disorder for doping purposes, identify risk factors related to the individual (anxiety)
Time frame: two months
In students with psychoactive drug use disorder for doping purposes, identify risk factors related to the individual (depression)
Time frame: two months
In students with psychoactive drug use disorder for doping purposes, identify risk factors related to the environment
Time frame: two months
In students with psychoactive drug use disorder for doping purposes, identify risk factors related to drugs.
Time frame: two months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 May 2022.
Related trials for Psychoactive Substance Use Disorder
RecruitingPhase 1
Evaluation of the Safety and Effects of Psychoactive Substances in People With Past Opioid Use
Opioid Use, Substance Use Disorders
RecruitingObservational study
Alcohol, Psychoactive Drugs, Analgesics and Evaluation in Penetrating Abdominal Trauma
Abdominal Injuries, Alcohol Intoxication
Recruiting
Predictive and Impact of Pain After 6 Months of Radiotherapy, in Head and Neck Cancer
Neuropathic Pain, Anxiety Disorder/Anxiety State
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Psychoactive Substance Use Disorder, run by University Hospital, Grenoble at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 May 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The main objective of the research is to characterize the motivations for psychoactive drugs consumption among medical and pharmacy students in France. (time frame: two months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 May 2022.